Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

Ritedose Pharmaceuticals has received the Food and Drug Administration’s approval for manufacturing and distributing generic albuterol sulfate inhalation solution, 0.5% (2.5 mg/0.5 ml). "Driven by the ...

Among patients with moderate-to-severe asthma who were receiving a range of inhaled glucocorticoid maintenance therapies, the risk of severe asthma exacerbation was significantly lower with as-needed ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma. 1 The BATURA Phase IIIb trial, ...

Severe exacerbation occurred in 5.1% of patients taking albuterol/budesonide compared with 9.1% of patients taking albuterol alone in the on-treatment efficacy population. Albuterol/budesonide ...

Randomized trial compares valved holding chambers for albuterol inhalation therapy ...